AG真人官方

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (鈥淓xicure鈥� or the 鈥淐ompany鈥�) (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company regained compliance with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the 鈥淩ule鈥�) based on the filing of its periodic reports on Form 10-Q to the United States Securities and Exchange Commission for the fiscal quarter ended March 31, 2025. The Company has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (鈥淣asdaq鈥�) confirming compliance with the Rule and stating that the matter has been resolved.

About Exicure

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see .

View source version on businesswire.com:

Media Contact:

Sarah Ellinwood, PhD

Kendall Investor Relations

[email protected]

Source: Exicure, Inc.